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Background: Improvements in ventilatory mechanics with tiotropium increases exercise 
tolerance during pulmonary rehabilitation. We wondered whether tiotropium also increased 
physical activities outside of pulmonary rehabilitation.
Methods: COPD patients participating in 8 weeks of pulmonary rehabilitation were studied in 
a randomized, double-blind, placebo-controlled trial of tiotropium 18 µg daily (tiotropium = 47, 
placebo = 44). Study drug was administered for 5 weeks prior to, 8 weeks during, and 12 weeks 
following pulmonary rehabilitation. Patients completed a questionnaire documenting participa-
tion in pre-deﬁ  ned activities outside of pulmonary rehabilitation during the 2 weeks prior to each 
visit. Patients who submitted an activity questionnaire at week 4 and on at least one subsequent 
visit were included in the analysis. For each patient, the number of sessions was multiplied with 
the duration of each activity and then summed to give overall activity duration.
Results: Patients (n = 46) had mean age of 67 years, mean baseline FEV1 of 0.84 L (33% 
predicted). Mean (SE) increase in duration of activities (minutes during 2 weeks prior to each 
visit) from week 4 (prior to PR) to week 13 (end of PR) was 145 (84) minutes with tiotropium 
and 66 (96) minutes with placebo. The increase from week 4 to week 25 (end of follow-up) 
was 262 (96) and 60 (93) minutes for the respective groups. Increases in activity duration from 
week 4 to weeks 17, 21, and 25 were statistically signiﬁ  cant with tiotropium. No statistical 
differences over time were observed within the placebo-treated group and differences between 
groups were not signiﬁ  cant.
Conclusions: Tiotropium appears to amplify the effectiveness of pulmonary rehabilitation as 
seen by increases in patient self-reported participation in physical activities.
Keywords: activity, chronic obstructive pulmonary disease, exercise, pulmonary rehabilita-
tion, tiotropium
Background
In patients with chronic obstructive pulmonary disease (COPD), physiological 
impairments imposed by the progressive nature of the disease, including airﬂ  ow 
limitation and hyperinﬂ  ation lead to reduced exercise tolerance. Reduced exer-
cise tolerance in turn leads to self-imposed activity limitation which then leads to 
deconditioning (ACCP/AACVPR 1997; GOLD 2005). Regular exercise training 
programs, such as those administered through pulmonary rehabilitation programs, 
consistently improve exercise endurance in patients with COPD (GOLD 2005). 
GOLD guidelines for COPD recommend exercise training for COPD patients with 
disease severity of GOLD stage II to IV (GOLD 2005). Presumably, improving 
ventilatory mechanics can lead to an increased ability to train and augment the 
beneﬁ  ts of pulmonary rehabilitation.International Journal of COPD 2008:3(1) 128
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Tiotropium 18 µg given once daily has been shown 
to provide sustained 24-hour improvements in airflow 
(Casaburi et al 2002), reduce hyperinﬂ  ation (Celli et al 2003; 
O’Donnell et al 2004a; Maltais et al 2005), and improve 
endurance time during constant work exercise (O’Donnell 
et al 2004a; Maltais et al 2005) due to prolonged muscarinic 
M3-receptor antagonism. We previously reported that tio-
tropium, in combination with pulmonary rehabilitation, 
improved ventilatory mechanics and augmented the exercise 
tolerance beneﬁ  ts of rehabilitation compared with a control 
group receiving rehabilitation training without tiotropium 
(Casaburi et al 2005).
As part of the protocol of this study, a simple question-
naire allowed the patients to track their participation in 
physical activities outside of the pulmonary rehabilitation 
program. In the current analysis, we retrospectively evaluated 
a group of patients completing an activities questionnaire 
to determine whether patients who participated in a clinical 
trial of exercise training with a combination of treatment 
with tiotropium and pulmonary rehabilitation were able to 
increase their physical activity outside of the pulmonary 
rehabilitation program.
Methods
Study design
A 25-week randomized, double-blind, parallel-group, 
placebo-controlled trial was conducted in patients with 
COPD to determine the efﬁ  cacy of tiotropium compared 
with placebo on exercise tolerance in patients participat-
ing in a pulmonary rehabilitation program (previously 
reported) (Casaburi et al 2005). The pulmonary rehabilita-
tion training program was an 8-week program consisting of 
treadmill training 3 times per week for at least 30 minutes 
each session. Patients were randomized to receive either 
tiotropium 18 µg once daily or placebo for 5 weeks prior 
to, 8 weeks during, and 12 weeks following pulmonary 
rehabilitation. Patients used a questionnaire to record 
activities they performed outside of the pulmonary reha-
bilitation sessions.
A retrospective analysis was performed on the subgroup 
of patients completing an activities questionnaire at week 4 
and on at least one other visit to determine whether patients 
were also able to increase their physical activity outside of 
pulmonary rehabilitation. This subgroup was also evalu-
ated for improvements in exercise tolerance, lung function, 
dyspnea, and quality of life. Week 4 (prior to pulmonary 
rehabilitation) was designated as the baseline. Changes in 
exercise participation were calculated from this timepoint 
because changes in exercise participation would not be 
expected without the beneﬁ  t of a pulmonary rehabilitation 
program in this population of severe and very severe COPD 
patients.
Participants
Patients included in the trial had a clinical diagnosis of 
COPD (Celli et al 2004), were at least 40 years of age, had a 
smoking history  10 pack-years, an FEV1  60% predicted 
(Morris et al 1988), and an FEV1/FVC ratio  70%. Patients 
were required to be candidates for pulmonary rehabilitation 
and to meet the rehabilitation program inclusion criteria. 
Patients were excluded if there was a history of asthma, 
moderate to severe renal impairment, moderate to severe 
symptomatic prostatic hypertrophy, bladder-neck obstruc-
tion, narrow angle glaucoma, regular use of daytime oxygen, 
history of lung resection, or recent myocardial infarction, 
arrhythmia, or hospitalization for heart failure. Patients were 
also excluded if they had a history of orthopedic, muscular 
or neurologic disease that would interfere with regular par-
ticipation in aerobic exercise or exercise testing, or if they 
had participated in pulmonary or cardiac rehabilitation in 
the preceding year.
Concomitant use of prn albuterol metered dose inhaler 
(100 µg/puff) was allowed throughout the study period. 
Concomitant use of theophylline preparations (excluding 
24-hour preparations), inhaled corticosteroids, and modest 
doses of oral corticosteroids was allowed. Oral β-agonists, 
long-acting β-agonists, short-acting anticholinergics and 
other investigational drugs were not allowed during the 
study. The protocol is consistent with the ethical standards 
of Helsinki. All patients provided written, informed consent 
and the study was approved by local institutional review 
boards.
Study protocol
The study protocol is outlined in Figure 1. An incremental 
treadmill test was performed at the screening visit prior 
to randomization. At the following visit, patients were 
randomized to receive either tiotropium 18 µg once daily 
(Boehringer Ingelheim Pharma GmbH and Co. KG, Ingel-
heim, Germany) or placebo via a dry powder inhalation 
device (HandiHaler®, Boehringer Ingelheim Pharma GmbH 
and Co. KG, Ingelheim, Germany) for the subsequent 
25 weeks. After 4 weeks of treatment, constant work rate 
treadmill exercise testing (zero incline) at 80% of the peak 
speed achieved in an incremental treadmill test was used 
to measure endurance time prior to the start of pulmonary Screening*
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rehabilitation. Constant work rate treadmill exercise testing 
was repeated at the end of pulmonary rehabilitation, and 
12 weeks after pulmonary rehabilitation had ended. At the 
screening visit and at weeks 4, 13, and 25, spirometry was 
used to determine morning pre-dose (trough) and post-dose 
forced expiratory volume in one second (FEV1). Dyspnea 
was assessed using the baseline (BDI) and transition dyspnea 
index (TDI) and health-related quality of life was assessed 
using the St. George’s Respiratory Questionnaire (SGRQ) 
(Mahler et al 1984; Jones et al 1992).
Activity questionnaire
At each clinic visit, patients were requested to complete an 
activity questionnaire (AQ) that was developed for this trial 
(Figure 2). This questionnaire captured participation in pre-
deﬁ  ned activities during the 2 weeks prior to each visit. Data 
were included in the analysis from patients who submitted 
an AQ at week 4 and on at least one subsequent visit. For 
each patient, the number of sessions was multiplied by the 
duration for each activity and then summed to give overall 
activity duration.
Statistical analysis
The sample size of the study was initially powered based 
on expected differences in exercise duration and not for 
other outcomes such as the AQ. Differences in calculated 
activity duration from week 4 to subsequent visits were 
compared within treatment groups using paired t-tests. 
Other patient outcomes such as FEV1, exercise endurance 
time, TDI and SGRQ were analyzed speciﬁ  cally in the 
subgroup of patients who completed the questionnaire. 
These data are presented as adjusted means and standard 
error based on an analysis of covariance model with 
treatment and center as factors and the baseline value as 
covariate. P values were calculated for descriptive pur-
poses only. Nominal statistical signiﬁ  cance was considered 
at p   0.05. The analysis was not corrected for multiple 
comparisons. (SAS/Stat software program, version 8.2, 
SAS, Cary, NC, USA)
Results
Results reported here are for the subgroup completing the 
AQ at week 4 (beginning of rehabilitation) and on at least 
one other subsequent visit.
Participants
Of 108 patients randomized to treatment (55 tiotropium; 
53 placebo), 91 had data available for efﬁ  cacy analysis 
for exercise endurance (47 tiotropium, 44 placebo), and 
46 completed the AQ at week 4 and on at least one other 
visit (25 tiotropium, 21 placebo) The characteristics of 
the AQ subgroup were similar to those of the full cohort 
(Tables 1 and 2).
Activities in addition to pulmonary 
rehabilitation
In the AQ subgroup, patients treated with tiotropium had a 
higher mean duration of participation in activities (in addi-
tion to pulmonary rehabilitation) during the 2 weeks prior to 
visits at weeks 4, 13, 17, 21, and 25 compared with patients 
taking placebo (Figure 3). At week 0 (prior to trial randomi-
zation), the mean (SE) duration of activities was 328 (100) 
and 155 (46) minutes in the tiotropium and placebo groups, 
respectively. The differences between groups were minor at 
Figure 1 Study design of 25-week randomized, controlled trial of tiotropium in COPD patients receiving pulmonary rehabilitation.
Abbreviations: CWR, constant work exercise; PR, pulmonary rehabilitation; AQ, activity questionnaire.
Note: *Spirometry, Baseline/Transitional dyspnea index, and St. George’s respiratory questionnaire also performed.International Journal of COPD 2008:3(1) 130
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week 4 prior to pulmonary rehabilitation (279 vs 253 minutes, 
Figure 3). Differences between groups were not statistically 
signiﬁ  cant.
The improvements in duration of activities from week 
4 (prior to rehabilitation) to subsequent visits were greater 
with tiotropium compared with placebo following pulmonary 
rehabilitation (week 13) and persisted during 12 weeks of 
follow-up (weeks 21 and 25) (Figure 4). The increases in 
activity duration from week 4 to weeks 17, 21, and 25 were 
statistically signiﬁ  cant in the tiotropium group (Table 3). No 
statistical differences over time were observed within the 
placebo treated group (Table 3).
The duration of individual activities over the 2-week 
period prior to each visit increased with pulmonary 
Figure 2 Contents of activity questionnaire administered to COPD patients participating in the trial.
Table 1 Patient demographics and baseline characteristics of the full cohort (n = 108) and for the activity questionnaire (AQ) 
subgroup (n = 46)
 Full  cohort    AQ  subgroup
 Tiotropium  Placebo  Tiotropium  Placebo
Total randomized (n)  55  53  25  21
Males (%)  55  59  56  52
Age (years)a  65.9 (8.8)  67.3 (6.9)  67.6 (7.2)  67.2 (7.4)
Duration of COPD (years)a  9.7 (7.6)  8.9 (6.6)  9.8 (8.0)  7.1 (4.4)
Smoking history (pack-years)a  58.6 (34.6)  58.8 (31.4)  57.9 (32.5)  50.2 (24.3)
Current smoker (%)  29.1  18.9  20.0  23.8
BMI (kg/cm2)a  25.0 (4.6)  26.8 (5.6)  24.4 (5.4)  26.2 (5.9)
FEV1 (L)a  0.82 (0.31)  0.94 (0.40)  0.78 (0.28)  0.91 (0.45)
FEV1 (% predicted)a  32.6 (12.4)  36.2 (12.2)  31.5 (12.3)  35.8 (12.4)
FVC (L)a  2.01 (0.68)  2.14 (0.85)  1.91 (0.62)  1.99 (0.87)
FEV1/FVC (%)a  41.5 (10.4)  44.6 (11.2)  41.6 (10.6)  46.0 (11.4)
Incremental treadmill test      
Maximum speed (mph)a  2.98 (0.87)  2.81 (0.98)  3.13 (0.92)  2.90 (0.98)
Endurance time (min)a  8.96 (2.84)  8.83 (3.60)  9.16 (3.02)  7.91 (2.34)
BDI focal scorea  5.7 (2.1)  5.7 (1.9)  5.9 (2.2)  5.9 (1.8)
SGRQ total scorea  50.4 (15.4)  46.6 (16.1)  48.8 (16.2)  47.6 (18.4)
Abbreviations: BMI, body mass index; FEV1, forced respiratory volume in one second; FVC, forced vital capacity; BDI, baseline dyspnea index; SGRQ, St. George’s respira-
tory questionnaire.
Note: *Mean (SD).
Activity questionnaire
For the purposes of this questionnaire a session of exercise will be defined as follows:
a continuous activity involving the legs
an activity outside of the usual activities of daily living (ie, walking upstairs to the bedroom)
activity outside of the pulmonary rehabilitation facility
For the last two weeks, record the frequency and duration of exercise sessions for the following exercises.
Total number of sessions y t i v i t c A
1. Walk
2. Jog
3. Treadmill
4. Stairs
5. Cycle
6. Rowing
7. Swimming
8. Other (list specific activities below)
Other activities: __________________________________________________________________________________________________
Average duration (minutes)International Journal of COPD 2008:3(1) 131
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rehabilitation in both the tiotropium and placebo groups; 
however, the summed duration for each activity was gener-
ally greater with tiotropium (Table 4).
Endurance time, spirometry, dyspnea, 
and quality of life
Previously reported results for the full cohort showed that 
tiotropium in combination with pulmonary rehabilitation 
led to greater improvements in endurance time, spirometry, 
dyspnea, and quality of life than rehabilitation alone 
(Casaburi et al 2005). These improvements were sustained 
for at least 3 months following pulmonary rehabilitation 
(Casaburi et al 2005). As with the preceding section, results 
reported here are for the subgroup completing the AQ at 
week 4 (beginning of rehabilitation) and on at least one 
other subsequent visit.
Figure 3 Mean (SE) minutes of activity during 2 weeks prior to each visit as reported through the activity questionnaire. Although not signiﬁ  cantly different by statistical 
analysis, patients receiving tiotropium reported approximately 216 minutes more physical activity as compared with patients receiving placebo at week 25.
Abbreviation: PR, pulmonary rehabilitation.
Table 2 Respiratory medications (proportion of population) used at any time during the trial period according to treatment group 
for the full cohort (n = 108) and the activity questionnaire (AQ) subgroup (n = 46)
Respiratory medication (%)  Full cohort    AQ subgroup 
 Tiotropium  n  = 55  Placebo n = 53  Tiotropium n = 25  Placebo n = 21
Anticholinergic 9  4  12  0
Long-acting beta-agonist  2  2  0  0
Inhaled steroid  46  32  56  29
Theophylline 18  21  20  14
Oral steroid  20  28  28  38
Oxygen 9  28  12  19
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In the AQ subgroup, tiotropium provided numerically 
larger improvements in mean endurance time compared with 
placebo after 4 weeks of treatment (difference prior to pulmo-
nary rehabilitation = 2.98 minutes), throughout the 8-week 
rehabilitation period (difference at end of pulmonary rehabilita-
tion = 6.13 minutes) and up to 12 weeks following rehabilitation 
(difference at end of follow-up = 9.95 minutes) (Figure 5).
In the AQ subgroup, the difference in mean pre-dose 
(trough) FEV1 (tiotropium – placebo) was 0.07 L at the end 
of the 8-week rehabilitation period (Week 13) and 0.08 L at 
the end of the study (Week 25). Mean post-dose FEV1 was 
improved over placebo with tiotropium by 0.13 L at the end 
of the 8-week rehabilitation period (Week 13) and by 0.10 L 
at the end of the study (Week 25).
Figure 4 Mean (SE) difference in duration of activities from week 4 (prior to pulmonary rehabilitation) to subsequent visits as reported through the activity questionnaire.  Patients 
receiving tiotropium reported on average 262 minutes more exercise at the end of the study whereas patients receiving placebo reported a gain of only 60 minutes.
Table 3 Mean (SE) duration of patient reported participation in physical activities outside of the pulmonary rehabilitation program in 
the treatment groups
 Tiotropium      Placebo*  
 n  Time  ∆ Week 4  p-value for  n  Time  ∆ Week 4  p-value for
   (min)  (min)  ∆ Week 4    (min)  (min)  ∆ Week 4
Prior to PR (week 4)  25  279 (41)  –  –  21  253 (50)  –  –
During PR (week 9)  25  322 (39)  43 (53)  0.425  17  349 (74)  110 (85)  0.212
End of PR (week 13)  22  403 (81)  145 (84)  0.098  16  353 (100)  66 (96)  0.506
Follow-up (week 17)  22  526 (75)  269 (63)   0.001  16  355 (102)  99 (106)  0.369
Follow-up (week 21)  19  432 (59)  159 (58)  0.013  17  394 (97)  125 (108)  0.266
Follow-up (week 25)  22  562 (86)  262 (96)  0.013  16  346 (95)  60 (93)  0.529
Abbreviation: PR, pulmonary rehabilitation.
Note: *p   0.05 for between group differences.
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Table 4 Mean (SE) duration of each activity in treatment groups
   Tiotropium    Placebo        Tiotropium    Placebo 
 n  Duration  n  Duration    n  Duration  n  Duration
   (minutes)    (minutes)      (minutes)    (minutes)
Walk         Cycling       
  Week 4  21  256 (42)  18  191 (43)    Week 4  1  90  1  120
  Week 9  20  251 (39)  14  239 (55)    Week 9  5  62 (10)  2  27 (3)
  Week 13  17  327 (99)  14  267 (61)    Week 13  1  60  1  20
  Week 21  18  270 (65)  15  303 (76)    Week 21  2  54 (6)  1  30
  Week 25  19  381 (95)  14  257 (49)    Week 25  4  219 (100)  1  60
Treadmill         Other       
  Week 4  5  84 (50)  2  34 (14)    Week 4  4  203 (75)  6  247 (62)
  Week 9  11  153 (31)  4  108 (43)    Week 9  5  97 (47)  7  276 (84)
  Week 13  12  140 (17)  2  210 (30)    Week 13  8  151 (25)  5  274 (97)
  Week 21  8  145 (57)  6  98 (17)    Week 21  6  324 (77)  5  267 (170)
  Week 25  12  132 (34)  4  51 (17)    Week 25  8  267 (52)  4  363 (271)
Stairs         Swimming       
  Week 4  3  59 (22)  6  33 (27)    Week 4  2  50 (30)  0  –
  Week 9  5  78 (29)  3  55 (43)    Week 9  2  78 (48)  0  –
  Week 13  6  60 (28)  3  37 (32)  Rowing      
  Week 21  5  26 (9)  4  49 (25)    Week 25  0  –  1  60
  Week 25  5  103 (87)  4  40 (15)  Jog 0  –  0  –
In the AQ subgroup, tiotropium improved the mean 
TDI Focal score over placebo by 1.36 units at the end of the 
8-week rehabilitation period (2.80 units with tiotropium vs 
1.45 units with placebo) and by 2.50 units at the end of the 
study (3.08 vs 0.58 units). Tiotropium improved the mean 
SGRQ Total score (a lower score indicates improvement) 
compared with placebo by 3.83 units at the end of the 8-week 
rehabilitation period (39.39 units with tiotropium vs 43.22 
units with placebo) and by 5.64 units at the end of the study 
(39.06 units vs 44.70 units, respectively).
Discussion
Pulmonary rehabilitation in patients with COPD has consist-
ently been reported to improve exercise tolerance, dyspnea 
and health-related quality of life (ACCP/AACVPR 1997). 
Tiotropium 18 µg once daily increases exercise endurance 
and patient-reported outcomes through sustained 24-hour 
improvements in airﬂ  ow and hyperinﬂ  ation (Casaburi et al 
2002; Celli et al 2003; O’Donnell et al 2004a; Maltais et al 
2005). A recent study has demonstrated that tiotropium can 
augment the beneﬁ  ts observed in pulmonary rehabilitation 
programs (Casaburi et al 2005). As part of this study, a 
simple questionnaire was used to track patient participation 
in physical activities outside of the pulmonary rehabilita-
tion program. Comparing the change from immediately 
prior to pulmonary rehabilitation to the conclusion of the 
pulmonary rehabilitation program, patients treated with tio-
tropium reported, on average, more than twice the number 
of minutes engaged in physical activities compared to the 
control group. Comparing the change from immediately 
prior to pulmonary rehabilitation to the end of the 12-week 
follow-up period, this increased to over 4 times the mean 
number of minutes compared to the control group at the 
end of the 12-week follow-up period. There was a pattern 
of larger improvements in the tiotropium group at all time 
points although the magnitude of improvement varied. The 
improvements in the tiotropium group were statistically sig-
niﬁ  cant whereas changes in the placebo group were not. None 
of the differences between groups (tiotropium – placebo) 
achieved statistical signiﬁ  cance; however, the sample size 
was small and the instrument was considered an exploratory 
secondary endpoint in the study. The results of the question-
naire suggest that tiotropium was associated with increased 
participation in physical activities in patients with severe 
and very severe COPD who were enrolled in a pulmonary 
rehabilitation program.
The standard outcome measures following interventions 
in COPD have included spirometry, lung volumes, dysp-
nea, exercise endurance, exacerbations and health status. 
Few studies have been devoted to objective examination 
of whether an intervention can lead patients to engage in 
increased physical activities. The primary reason is lack of 
tools that can document the outcome. Measures of patient 
perception of dyspnea, such as the transition dyspnea index, 
indicate that the patient is able to engage in activities with 
less breathlessness, or engage longer in activities, or take on International Journal of COPD 2008:3(1) 134
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more strenuous activities; however, the instrument does not 
document the degree or duration of participation in physical 
activities (Mahler et al 1984). Health status instruments such 
as the Chronic Respiratory Disease Questionnaire and the St. 
George’s Respiratory Questionnaire also do not document the 
degree or duration of participation (Guyatt et al 1987; Jones 
et al 1992). Exercise testing, such as incremental or constant 
work cycle ergometry, can indicate that patients are able to 
engage in activities for longer periods of time, provided the 
intervention is efﬁ  cacious but these tests are laboratory based. 
The Pulmonary Function Status Questionnaire has sub-scores 
of daily activities, household tasks, meal preparation, and 
grocery shopping but this questionnaire does not indicate 
duration of participation (Weaver et al 1992). Therefore, a 
tool with the ability to objectively document home-based 
activity would be desirable to measure the effect of interven-
tions in patients with COPD.
The present analysis supports previous information that 
interventions in COPD can result in improvements in the 
ability to participate in physical tasks. In a 6-week double-
blind, randomized, placebo-controlled study, tiotropium 
resulted in a 21% improvement in endurance time during 
constant work cycle ergometry set at 75% of the maximum 
work rate of a preceding symptom limited incremental test 
(O’Donnell et al 2004a). These results were corroborated 
in a subsequent clinical trial using a similar design in 
which tiotropium improved constant work cycle ergom-
etry duration by 69% vs 10% in the control group (Maltais 
et al 2005). In addition, improvements were observed in a 
second test on the same test day performed 8 hours post 
dose (Maltais et al 2005). Salmeterol has also demon-
strated improvements in constant work cycle ergometry in 
a single-center crossover study, although improvements in 
exercise duration with long-acting β-agonists have not been 
consistently observed (Rennard et al 2001; Aalbers et al 
2002; O’Donnell et al 2004b). Pulmonary rehabilitation, 
however, is the intervention that appears to produce the 
largest improvements in exercise training in COPD patients 
(ACCP/AACVPR 1997). For all of the aforementioned 
interventions, information is scarce regarding objective 
documentation of participation in physical activities in the 
patients’ home environment.
There are several limitations to the present report. The 
questionnaire was developed as a tracking instrument without 
Figure 5 Mean (SE) endurance times resulting from the combination of tiotropium and pulmonary rehabilitation in the subgroup of patients who completed the activity 
questionnaire. Patients receiving tiotropium continued to increase their measured exercise endurance during the 12-week period following pulmonary rehabilitation.
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standard psychometric development processes. For example, 
patient focus groups were not held to identify which activities 
are most important to rehabilitation patients. In addition, 
sufﬁ  cient information from the questionnaire was obtained 
only in a subpopulation of patients as this was not considered 
a primary outcome. The results of the questionnaire cannot 
be generalized to a broader COPD population as the COPD 
patients eligible for pulmonary rehabilitation represent the 
severe end of the COPD spectrum. In addition, the sample 
size does not provide adequate power to determine statisti-
cal signiﬁ  cance between the active treatment and the control 
groups. Nevertheless, patterns and trends in the results of 
the questionnaire support the beneﬁ  ts observed for other 
outcomes in both the full cohort as described by Casaburi 
et al (2005) and the subgroup having adequate activity ques-
tionnaire data in the present analysis. Furthermore, although 
the results suggest that improvements can be maintained 
following pulmonary rehabilitation, the follow-up period in 
the present study was limited to 12 weeks and further, longer 
term data is needed. Finally, it should also be recognized that 
the use of an accelerometer in studies of activity provide 
objective measures of movement and would be needed to 
validate activity-based questionnaires such as the one used 
in the present study.
Conclusions
In summary, a previously published clinical trial showed that 
tiotropium 18 µg once daily in addition to pulmonary reha-
bilitation leads to greater improvements in endurance time 
than rehabilitation alone in patients with COPD (Casaburi 
et al 2005). The results of an activity questionnaire in the 
reported study showed increases in patient self-reported 
participation in physical activities outside of pulmonary 
rehabilitation thereby supporting the observation that tio-
tropium ampliﬁ  es the effectiveness of pulmonary rehabili-
tation. While this observation corroborates the signiﬁ  cant 
improvements in treadmill endurance time with tiotropium 
relative to the control group documented in the pulmonary 
rehabilitation trial, deﬁ  nitive conclusions are limited as not 
all patients submitted the activity form. The simple, self-
reported activity questionnaire described here can be used as 
a basis for development and testing of a more efﬁ  cient and 
applicable tool to help track physical activities performed 
outside of pulmonary rehabilitation facilities.
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